Select Publications

Conference Abstracts

Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in Annals of Oncology, OXFORD UNIV PRESS, Singapore, SINGAPORE, Vol. 28, pp. x78 - x79, presented at ESMO Asia Congress, Singapore, SINGAPORE, 17 November 2017 - 19 November 2017, http://dx.doi.org/10.1093/annonc/mdx662.006

Hao J; Graham P; Chang L; Ni J; Beretov J; Deng J; Bucci J; Cozzi P; Li Y, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Deng J; Duan W; Graham P; Bucci J; Li Y, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hao J; Graham PH; Chang L; Ni J; Wasinger V; Beretov J; Bucci J; Cozzi P; Li Y, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001

Ni K, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro.', in CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro., AACR 2014, presented at AACR 2014

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., The St George & Sutherland Medical Research Symposium, presented at The St George & Sutherland Medical Research Symposium

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., LOWY cancer symposium, presented at LOWY cancer symposium

Ni K, 2012, 'Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy.', in Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy., 13th Australasian Prostate Cancer Conference, presented at 13th Australasian Prostate Cancer Conference


Back to profile page